GET THE APP

Treatment of new skin diseases using a new lotion (Oronsfranklo) | 58106
Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

+44 1478 350008

Treatment of new skin diseases using a new lotion (Oronsfranklo)


Joint Event on 7th International Conference on Clinical Trials & 12th World CADD & Drug Delivery Summit

September 24-26, 2018 | Chicago, USA

Oronsaye Fe

University of Benin City, Nigeria

Posters & Accepted Abstracts: J Clin Trials

Abstract :

Background: The emergence of new diseases of unknown etiology is a common health challenge in developing countries. These diseases have defiled all known medications. They affect the upper region of the body, particularly the face, neck and the jaw. Methods: One hundred subjects compressing 20 children, 50 adults 20 elderly subjects who were discovered having bumps �??as it is called�?? on the face scailp neck were randomly recruited for the study Their consent was obtained verbally.: The subjects were given the lotion orondfranklo(R)which was applied to the affected areas twice daily, preferably morning and evening. The lotion is currently been investigated for its toxicity so that it can be recommended for systemic administration. The lotion is exclusively for external use. This lotion has been successfully used for treating both superficial fungal and bacterial infections. Results: the most dramatic effect of the lotion is the fact that during its application, a successful clinical response was achieved within three days. Therefore, it is rightly called, the �??three days cure�??. Conclusion: This study presents, the novel effecCormerce and industry in Nigeria as a pre-registration requirements bb t of the lotion. The lotion has already been registered with the ministry of commerce and industry, Nigeria as pre-registration requirement by Nafdac Nigeria before they certify any drug for commercial use. So Oronsfranklo is the trademarks assigned to this lotion by there m9iinistry of commerce and industry Nigeria.

Biography :

   

Top